<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040534</url>
  </required_header>
  <id_info>
    <org_study_id>P01499</org_study_id>
    <nct_id>NCT00040534</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of an oral Farnesyl
      Protein Transferase

      Inhibitor (SCH 66336) when given in combination with Gemcitabine and Cisplatin in patients
      with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">22</enrollment>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farnesyl Protein Transferase Inhibitor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced cancer for which there is no treatment available which would have a
             reasonable chance of disease palliation or cure

          -  Age greater than or equal to 18.

          -  SWOG performance Status less than or equal to 2.

          -  Meets protocol requirements for specified laboratory values.

          -  Written informed consent and cooperation of patient.

        Exclusion Criteria:

          -  Prior treatment with an FPTI

          -  Knowledge of intracranial metastases or carcinomatous meningitis.

          -  Poor medical risks because of nonmalignant systemic disease or uncontrolled active
             infection.

          -  Medical conditions that would interfere with taking oral medications.

          -  Significant uncontrolled diarrhea.

          -  Chemotherapy, radiotherapy or major surgery within 4 weeks; full recovery from prior
             treatment.

          -  Concomitant use of CYP3A inhibitors/inducers per protocol.

          -  Known HIV positivity or AIDS-related illness.

          -  Pregnant or nursing women.

          -  Men or women of childbearing potential who are not using an effective method of
             contraception.

          -  Concurrent chemotherapy, hormonal therapy, radiotherapy or immunotherapy.

          -  QTc prolongation (&gt;440 msecs) at baseline.

          -  Patients with previous high-dose therapy requiring stem cell rescue or bone marrow
             transplant, or irradiation to &gt;30% of bone marrow-containing areas.

          -  Patients that have received Mitomycin-C or nitrosoureas.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep;62(4):631-46. Epub 2007 Dec 6.</citation>
    <PMID>18058098</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2002</study_first_submitted>
  <study_first_submitted_qc>June 28, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2002</study_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

